The Impact of Outcome Measures for Responder Analyses in Placebo‐Controlled Trials of Pharmacological Treatments for Neuropathic Pain
European Journal of Pain · 2026-11 · 30 (10)
DOI: 10.1002/ejp.70448 ↗Kurz gefasst
Metaanalyse in der Zeitschrift European Journal of Pain, online erschienen am 06.11.2026. Verfasst von Nanna Brix Finnerup und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Medicine, Danish Pain Research Center, Aarhus University, Aarhus, Denmark. Hauptthemen laut MEDLINE: Neuralgia, Analgesics, Outcome Assessment, Health Care. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Dichotomous responder outcomes, including ≥ 30% and ≥ 50% pain reduction, patient‐reported pain relief, and Patient Global Impression of Change (PGIC), are widely used in trials assessing interventions for neuropathic pain and have been suggested to be comparable, but their differences and influence on estimated treatment effects remain uncertain.
Methods
The study presents secondary analyses of 222 double‐blind RCTs in neuropathic pain. Trials assessing drugs with recommended or inconclusive recommendations reporting at least two different dichotomous outcomes were included. Risk differences, numbers needed to treat (NNT), and relative risks were calculated.
Results
Ninety‐one trials were included. Across 76 trials, the risk difference was higher for ≥ 30% than ≥ 50% pain reduction (difference 0.023, 95% CI 0.012–0.034; p < 0.001), corresponding to lower NNTs for ≥ 30% pain reduction (8.8 vs. 11.1). PGIC‐based outcomes yielded numerically lower NNTs than ≥ 50% pain reduction and were similar to ≥ 30% pain reduction, although variability was substantial. Within 31 trials reporting all outcomes, ≥ 30% pain reduction and PGIC showed comparable NNTs on average, whereas ≥ 50% pain reduction consistently produced higher NNTs. Comparisons involving pain relief scales were limited by sparse data and heterogeneity.
Conclusions
Estimated treatment effects in neuropathic pain trials depend on the responder definition used. Outcomes based on ≥ 50% pain reduction yield systematically higher NNTs than ≥ 30% pain reduction and PGIC, indicating lower assay sensitivity. Standardization of outcome measures may improve interpretability and comparability of analgesic efficacy. Significance Indicating the main aspects where this work adds significantly to existing knowledge in the field, and if appropriate to clinical practice. We show that stricter responder thresholds (≥ 50% pain reduction) attenuate detectable treatment effects compared with ≥ 30% pain reduction. This has direct implications for meta‐analyses and comparisons of treatment effects as well as for clinical trials, as suboptimal endpoint choice may contribute to underpowered trials and premature discontinuation of potentially effective therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Medicine, Danish Pain Research Center, Aarhus University, Aarhus, Denmark.
- Department of Neurology, Aarhus University, Aarhus, Denmark.
- CHU Clermont-Ferrand, Neuro-Dol, Inserm, Université Clermont Auvergne, Clermont-Ferrand, France.
- Department of Human Neuroscience, Sapienza University, Rome, Italy.
- Department of Neurology, University Hospital Schleswig-Holstein, Kiel, Germany.
- The Nuffield Department of Clinical Neuroscience, The University of Oxford, Oxford, UK.
ORCID-Profile: Nanna Brix Finnerup
Zitieren
APA
Finnerup, N. B., Gylfadottir, S. S., Moisset, X., Truini, A., Baron, R., Bennett, D. L., Calvo, M., Ciampi de Andrade, D., Dougherty, P. M., Enax-Krumova, E. K., Ferraro, M. C., Gilron, I., Hietaharju, A., Hohenschurz-Schmidt, D., Hosomi, K., Kemp, H. I., McNicol, E., Phalip, J., Price, T. J., …, & Haroutounian, S. (2026). The Impact of Outcome Measures for Responder Analyses in Placebo‐Controlled Trials of Pharmacological Treatments for Neuropathic Pain. European Journal of Pain, 30(10). https://doi.org/10.1002/ejp.70448
Vancouver
Finnerup NB, Gylfadottir SS, Moisset X, Truini A, Baron R, Bennett DL, et al. The Impact of Outcome Measures for Responder Analyses in Placebo‐Controlled Trials of Pharmacological Treatments for Neuropathic Pain. European Journal of Pain. 2026;30(10). doi:10.1002/ejp.70448
BibTeX
@article{Finnerup2026,
author = {Finnerup, Nanna Brix and Gylfadottir, Sandra Sif and Moisset, Xavier and Truini, Andrea and Baron, Ralf and Bennett, David L and Calvo, Margarita and Ciampi de Andrade, Daniel and Dougherty, Patrick M and Enax-Krumova, Elena K and Ferraro, Michael C and Gilron, Ian and Hietaharju, Aki and Hohenschurz-Schmidt, David and Hosomi, Koichi and Kemp, Harriet I and McNicol, Ewan and Phalip, Jules and Price, Theodore J and Raja, Srinivasa N and Ramirez Piriz, Cristina and Rice, Andrew S C and Smith, Blair H and Taule-Lim, Nina and Vollert, Jan and Wandrey, Jan D and Zunaid, Mohammad D and Attal, Nadine and Haroutounian, Simon},
title = {The Impact of Outcome Measures for Responder Analyses in Placebo‐Controlled Trials of Pharmacological Treatments for Neuropathic Pain},
journal = {European Journal of Pain},
year = {2026},
volume = {30},
number = {10},
doi = {10.1002/ejp.70448}
}
EUVIMED